1977-07-7
1977-07-7
Chemical Structure
Deschloroclozapine
- CAS No.: 1977-07-7
- Formula:C18H20N4
- Molecular Weight:292.39
IUPAC Name: 11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
InChIKey: VQHITFFJBFOMBG-UHFFFAOYSA-N
SMILES: CN1CCN(C2=NC3=CC=CC=C3NC4=CC=CC=C42)CC1
Biological Activity: Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deschloroclozapine | 99.93% | Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deschloroclozapine (Standard) | ≥98% | Deschloroclozapine (Standard) is the analytical standard of Deschloroclozapine (HY-42110). This product is intended for research and analytical applications. Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Maggs JL, et al. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 1995;275(3):1463-1475. [Content Brief]
- [2]. Hu F, et al. 18F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. Eur J Med Chem. 2021;213:113047. [Content Brief]
- [3]. Upright NA, et al. Effect of chemogenetic actuator drugs on prefrontal cortex-dependent working memory in nonhuman primates. Neuropsychopharmacology. 2020;45(11):1793-1798. [Content Brief]
